Compare Inovio Pharmaceuticals Inc (INO) vs Southwest Airlines Co (LUV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Southwest Airlines Co — how do they compare? Inovio Pharmaceuticals Inc trades at $0.73 (market cap $78.55M), while Southwest Airlines Co trades at $45.21 (market cap $22.27B). The key difference: Southwest Airlines Co is far larger — about 283.5× Inovio Pharmaceuticals Inc's market cap, and Southwest Airlines Co pays a 1.58% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | LUV | |
|---|---|---|
Market Cap | $78.55M | $22.27B |
Sector | Health | Industrials |
52-Week High | $2.87 | $54.80 |
52-Week Low | $0.66 | $29.67 |
Enterprise Value | $49.56M | $25.37B |
Dividend Yield | — | 1.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.
Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.
Southwest Airlines (LUV) trades at $44.9, down 4.57% on the day, with a bearish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1 2026, while revenue growth is projected to rise to $30.1B in 2026. Recent news highlights board appointments and initiatives to attract business travelers, amid a volatile fuel cost environment.
LUV presents a cautious opportunity with a consensus price target of $53.86 implying upside, supported by improving cash flow and dividend payments. Risks include fuel price volatility, execution on new business offerings, and competitive pressures, requiring careful monitoring of earnings consistency and cost management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →
